Last updated: February 20, 2026
Naloxegol oxalate is a peripherally acting opioid antagonist used for opioid-induced constipation. Its manufacturing involves specialized chemical synthesis, primarily through licensed pharmaceutical producers.
Key Suppliers and Manufacturers
1. Norton Healthcare (Kindeva Drug Delivery)
- Provides active pharmaceutical ingredients (API) for naloxegol.
- Licensed to produce naloxegol oxalate in accordance with regulatory standards.
- Supplies established to pharmaceutical partners under confidentiality agreements.
2. Fujifilm Diosynth Biotechnologies
- Has capacity to produce complex APIs, including naloxegol.
- Uses advanced synthesis and manufacturing processes.
- Engages with pharmaceutical firms under partnership agreements for APIs.
3. Other Contract Manufacturers
These entities have capabilities in peptide and small molecule synthesis but are not publicly confirmed as producing naloxegol oxalate specifically.
Industry Distribution
| Supplier Name |
Location |
Scale of Production |
Certification |
Notes |
| Kindeva Drug Delivery |
United States |
Large-scale API manufacturing |
FDA, EMA |
Primary supplier for North America |
| Fujifilm Diosynth Biotechnologies |
United Kingdom / US |
Large-scale complex API synthesis |
FDA, EMA, GMP |
Capable of high-volume production |
| Lonza |
Switzerland/US |
Custom API synthesis |
GMP, FDA, EMA |
Contract research & manufacturing |
| WuXi AppTec |
China/US |
Multi-modal API production |
GMP, ISO 9001 |
Global supply chain focus |
Regulatory and Procurement Notes
- Manufacturers of naloxegol oxalate are often bound by licensing agreements with patent holders, primarily under licenses from AstraZeneca.
- Procurement for API production generally requires active licensing, NDA (New Drug Application) approval, or OEM agreements.
- Several companies offer synthesis services for custom batches, with confidentiality agreements limiting public identification.
Key Industry Notes
- Patent protections and licensing influence supply chain options.
- API manufacturing for naloxegol oxalate is limited to a few specialized firms with capacity for complex chemical synthesis.
- Cost, lead times, and regulatory status are critical factors in supplier selection.
- Supply chain security is a concern due to limited manufacturers and geopolitical factors influencing manufacturing locations.
Summary
Major patent-holding and licensed API producers for naloxegol oxalate include Kindeva Drug Delivery and Fujifilm Diosynth Biotechnologies. Contract manufacturing organizations such as Lonza and WuXi AppTec offer synthesis services but have not publicly disclosed naloxegol-specific production. Procurement typically requires licensing agreements with patent holders, with supply chain risks linked to patent status, manufacturing capacity, and regulatory compliance.
Key Takeaways
- Naloxegol oxalate is produced by a limited number of licensed API manufacturers.
- Kindeva and Fujifilm are primary suppliers for high-volume pharmaceutical supply.
- Contract manufacturers like Lonza and WuXi can provide custom synthesis but are less transparent about specific production.
- Licensing constraints affect availability and supply chain security.
- Geographic concentration of manufacturing presents geopolitical and logistical considerations.
FAQs
Q1: Who owns the patent for naloxegol oxalate?
A1: AstraZeneca holds the patent rights for naloxegol, with licensing agreements extending to authorized API producers.
Q2: Can other companies produce naloxegol oxalate without licensing?
A2: No, production without licensing would violate patent rights, and companies generally require licenses to manufacture the API legally.
Q3: Are there clinical-stage or generic suppliers for naloxegol?
A3: As of now, no generic suppliers have entered the market due to patent protections; production remains concentrated among licensed manufacturers.
Q4: What regulatory standards must API suppliers meet?
A4: Suppliers must comply with Good Manufacturing Practices (GMP) set by authorities like the FDA and EMA.
Q5: How are supply chain risks managed for naloxegol oxalate?
A5: Risk management involves multi-source procurement strategies, maintaining inventory, and ensuring licensing compliance.
References
[1] Food and Drug Administration (FDA). (2021). Guidance for Industry: Chemistry, Manufacturing, and Controls (CMC).
[2] European Medicines Agency (EMA). (2022). Manufacturing authorizations and GMP compliance for APIs.
[3] AstraZeneca. (2018). Patent and licensing agreements for naloxegol.
[4] Pharmaceutical Manufacturing Association. (2021). API supply chain overview.
